Skip to content

Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling

Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04936620
Acronym
DISCUS
Enrollment
222
Registered
2021-06-23
Start date
2021-10-08
Completion date
2028-06-30
Last updated
2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injuries

Keywords

Decompression, surgical; Neurosurgery; Paralysis

Brief summary

QUESTION. Does duroplasty improve outcome after spinal cord injury? WHAT DO WE STUDY? We will investigate whether performing a surgical procedure called duroplasty improves outcomes after spinal cord injury. WHY SPINAL CORD INJURY? Spinal cord injury is a devastating condition that causes permanent disability such as paralysis, numbness and loss of bladder and bowel control. Currently, there are no treatments shown to improve outcome after spinal cord injury. WHAT IS DUROPLASTY? Duroplasty is an operation that involves opening the tough membrane around the cord, called the dura, and stitching a patch of artificial dura to expand the space around the swollen cord. WHY IS DUROPLASTY BEING STUDIED? Based on our preliminary evidence, we think that the dura causes cord pressure after injury. We have shown in a small study of patients that performing this operation safely and effectively reduces pressure on the injured cord. WHO IS ELIGIBLE? Adult patients with severe spinal cord injuries in the neck who will have surgery within 72 hours. WHAT TREATMENT? Those who agree to take part will be allocated by chance (like tossing a coin) to standard treatment or standard treatment plus duroplasty. Some patients will also be asked to take part in a smaller study that involves placing probes at the injury site. WHERE? Initially, we will recruit patients from U.K. Major Trauma Centres. Most assessments will be done in U.K. Spinal Injury Centres. Later on, we we also started recruiting from overseas. HOW LONG? We aim to recruit 222 - 260 patients over 4 years. Patients will be followed up for a year. WHAT DO WE ASSESS? Patients will be assessed (using questionnaires and by examination) how well they can use their hands, walk, control their bladder and bowel and their quality of life. Some of these assessments will be repeated at 3, 6 and 12 months after surgery. WHAT IS THE OPTIONAL MECHANISTIC STUDY? DISCUS includes an optional study for at least 50 patients who will take part in the randomised controlled trial. The aim of the mechanistic study is to determine how duroplasty improves outcome, i.e. whether duroplasty reduces cord compression, improves blood flow to the injured cord perfusion, improves cord metabolism and reduces cord inflammation. WHAT IS THE OPTIONAL INFORMATION STUDY? For the first two years, a study called QuinteT Recruitment Intervention (QRI) is designed to optimise patient recruitment and informed consent in the trauma setting.

Detailed description

RESEARCH QUESTION: After severe traumatic spinal cord injury (TSCI), does the addition of dural decompression to bony decompression (includes laminectomy) improve muscle strength in the limbs at 6 months, compared with bony decompression alone? BACKGROUND: TSCI is a devastating condition that affects about 1,000 people in the UK annually. Most remain disabled, tetraplegic or wheelchair bound and are dependent on carers with significant cost to patients, carers and the NHS. Surgery aims to reduce spinal deformity, stabilise the spine and achieve bony decompression of the cord. To date, no treatments have been shown to improve outcome. AIMS / OBJECTIVES: The primary aim is to determine if, in patients with acute, severe TSCI, the addition of dural decompression to bony decompression improves muscle strength. We hypothesise that, after TSCI, the cord swells and is compressed against the dura. Secondary objectives are to assess patient impact i.e. functional outcomes, health related quality of life (HRQoL), complication rates and mortality. Mechanistic sub-studies aim to determine if the addition of duroplasty improves cord perfusion, reduces cord ischaemia and cord inflammation. METHODS: This is a prospective, phase III, multicentre randomised controlled trial (RCT). We aim to recruit 222 adults with acute, severe cervical TSCI (American spinal injuries association Impairment Scale (AIS) grade A, B or C) who will be randomised 1:1 to undergo bony decompression alone versus bony decompression with duroplasty. Patients and assessors will be blinded to study arm. The primary outcome is change in AIS motor score (AMS) at 6 months compared with admission (Delta-AMS); secondary outcomes will assess function (grasp, walking, urinary + anal sphincters), HRQoL, complications, need for further surgery and mortality, assessed at baseline, 3 months, 6 months and 12 months from randomisation. A subgroup of 50 patients (25 per arm) will also have observational monitoring from the injury site using a pressure probe (intraspinal pressure ISP, spinal cord perfusion pressure SCPP) and microdialysis (MD) catheter (cord metabolism: tissue glucose, lactate, pyruvate, lactate-to-pyruvate ratio (LPR), glutamate, glycerol); cord inflammation: tissue chemokines/cytokines. Initially, patients were only recruited from UK major trauma centres (MTCs). DISCUS is now also recruiting patients from International sites. TIMELINES FOR DELIVERY: The initial study duration was 72 months and includes 6 months set-up, 48 months recruitment, 12 months to complete follow-up and 6 months for data analysis and final reporting of results. There will be a formal stop/go review at month 15 (after 9 months of recruitment) to ensure a minimum of 4 sites have been opened and 8 patients randomised. If these targets are met, the trial will recruit for a further 36 months. Data from the pilot will be included in the final analysis. Recruitment has been extended to end on 30 June 2027. ANTICIPATED IMPACT AND DISSEMINATION: It is anticipated that the addition of duroplasty to standard of care will improve muscle strength in patients; this has obvious benefits for patients and their carers as well as substantial gains for the NHS and society including economic implications. If this RCT shows that the addition of duroplasty to standard treatment is beneficial, it is anticipated that duroplasty will become standard NHS care in all 26 UK MTCs, and internationally. Participants will be informed of study findings via the Surgical Intervention Trials Unit (SITU) website and the Spinal Injuries Association (SIA).

Interventions

PROCEDUREDuroplasty

Expansion Duroplasty

PROCEDURESpinal surgery

Spinal surgery including laminectomy

Sponsors

St George's, University of London
Lead SponsorOTHER
St George's University Hospitals NHS Foundation Trust
CollaboratorOTHER
St. Mary's University, Twickenham
CollaboratorOTHER
University of Bristol
CollaboratorOTHER
Ohio State University
CollaboratorOTHER
University of Cambridge
CollaboratorOTHER
University of Oxford
CollaboratorOTHER
Buckinghamshire Healthcare NHS Trust
CollaboratorOTHER
Paracelsus Medical University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Participants, some care providers (ie: physiotherapists) and outcome assessor will be blinded.

Intervention model description

Phase III clinical trial: randomised, controlled, double blind, multi-centre, superiority \+ Optional mechanistic study

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥16 years 2. Severe cervical (C2 - T1) traumatic spinal cord injury (AIS grade A-C) 3. Deemed to require and be suitable for surgery that includes laminectomy by local surgeon 4. Surgery within 72 hours of traumatic spinal cord injury 5. Able to provide informed consent or consultee declaration or proxy consent.

Exclusion criteria

1. Dural tear due to traumatic spinal cord injury 2. Life-limiting or rehabilitation-restricting co-morbidities 3. Thoracic or lumbar traumatic spinal cord injury 4. Other central nervous system disease

Design outcomes

Primary

MeasureTime frameDescription
Change in AIS motor score6 months versus baselineChange in American Spinal Injury Association Impairment Scale total limb motor score at 6 months

Secondary

MeasureTime frameDescription
Change in AIS light touch score6 months versus baselineChange in American Spinal Injury Association Impairment Scale total light touch sensory score
Change in AIS pin prick score6 months versus baselineChange in American Spinal Injury Association Impairment Scale total pin prick sensory score
Change in AIS grade6 months versus baselineChange in American Spinal Injury Association grade
CUE-Q6 monthsCapabilities of upper extremity-questionnaire (CUE-Q)
Grip strength6 monthsHand grip strength assessed with dynamometer
WISCI II6 monthsWalking Index for Spinal Cord Injury version ii
SCIM III6 monthsSpinal Cord Independence Measure version III
SF-366 months, 12 monthsShort Form survey 36
Spinal re-operations12 monthsNumber of reoperations on spine
Adverse events12 monthsProcedure Specific complications and adverse events
Mortality12 monthsMortality
Length of hospital stay12 monthsLength of hospital stay
MRI2 weeks, 6 monthsMagnetic resonance imaging of cervical spine
Injury site physiology and metabolism (optional)Up to 5 days after surgeryOptional mechanistic study: Mean daily intraspinal pressure, spinal cord perfusion pressure, tissue glucose, lactate, pyruvate, glycerol, glutamate, cytokines measured from the injury site

Countries

Austria, Belgium, China, Czechia, Denmark, Finland, Germany, Israel, Slovenia, Spain, Sweden, United Kingdom

Contacts

CONTACTSophie Reynolds
discus@nds.ox.ac.uk079 17100953
CONTACTGhazal Ebrat
gebrat@sgul.ac.uk
PRINCIPAL_INVESTIGATORMarios C Papadopoulos

St George's, University of London, U.K.

PRINCIPAL_INVESTIGATORSamira Saadoun

St George's, University of London, U.K.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 7, 2026